{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000004","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.994237+00:00","generated_at":"2026-06-20T16:52:05.931417+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65","bullets":["FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.","Royalty revenue guided $445M-$455M (>20% growth); EBITDA $415M-$440M (>30% growth).","Non-GAAP diluted EPS guidance $2.50-$2.65; up to $150M share repurchases under $750M authorization.","Anticipates two ENHANZE SC launches (efgartigimod, atezolizumab) and four Phase 3 data readouts in 2023.","Completed Antares Pharma acquisition in 2022; expects continued strength in DARZALEX SC and Phesgo royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000004","json":"https://secwatch.observer/filing/0001159036-23-000004.json","markdown":"https://secwatch.observer/filing/0001159036-23-000004.md","text":"https://secwatch.observer/filing/0001159036-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/halo-20230110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:52:05.931417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2a70308d458326a9008ac621bb57e392d734e24","claim":"HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million, EPS $2.50 to $2.65. Guidance initiated.","evidence_excerpt":"Halozyme expects total revenue of $815 million to $845 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"$815 million to $845 million"},{"label":"EPS","value":"$2.50 to $2.65"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}